<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Midlife <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e>, including <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, dyslipemia, and an unhealthy lifestyle, have been linked to subsequent incidence, delay of <z:hpo ids='HP_0003674'>onset</z:hpo>, and progression rate of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Conversely, optimal treatment of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> prevents and slows down age-related <z:e sem="disease" ids="C0009241" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The impact of <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy on cognitive outcome in patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo> was assessed in large trials which demonstrated a reduction in progression of MRI white matter hyperintensities, in <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> and in incidence of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Large-scale database correlated <z:chebi fb="0" ids="35664">statin</z:chebi> use and reduction in the incidence of <z:hpo ids='HP_0000726'>dementia</z:hpo>, mainly in patients with documented <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, but clinical trials failed to reach similar conclusions </plain></SENT>
<SENT sid="4" pm="."><plain>Whether a multitargeted intervention would substantially improve protection, quality of life, and reduce medical cost expenditures in patients with lower risk profile has not been ascertained </plain></SENT>
<SENT sid="5" pm="."><plain>This would require appropriately designed trials targeting large populations and focusing on <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> as a primary outcome endpoint </plain></SENT>
</text></document>